CORPORATIONS-SHAREHOLDERS-SETTLEMENT OF DERIVATIVE SUITS UNDER THE FEDERAL RULES

Plaintiff, a minority stockholder in the Kaiser-Frazer Corporation, objected to the approval by a federal district court of a settlement in a stockholder\u27s derivative action against various directors of the company and several firms in which they were interested. The compromise covered a series of similar suits filed in state and federal courts, involving contracts negotiated by the directors with defendant companies and alleged manipulations through security purchases preceding a projected issue of stock in 1948. The court had approved the compromise under rule 23(c) of the Federal Rules of Civil Procedure. Plaintiff contended that the settlement was collusive and a fraud on other members of the class represented by defendant stockholder in the compromise negotiations. On appeal from the judgment approving the compromise, held, affirmed, one judge dissenting. The policy underlying rule 23(c) is best served if the interests of the corporation are protected; where the trial court has exercised adequate supervision over the terms of a settlement, its findings are conclusive absent clear error. Masterson v. Pergament, (6th Cir. 1953) 203 F. (2d) 315, cert. den. 346 U.S. 832, 74 S.Ct. 33 (1953)

Griswold: The Fifth Amendment Today

A Review of The Fifth Amendment Today. By Erwin N. Griswol

Legislation - Witness Immunity Act of 1954 - Constitutional and Interpretative Problem

The passage in August, 1954 of a federal statute granting immunity under specified conditions to witnesses before congressional committees and in the federal courts marks a third legislative experiment designed to soften the effect of the Fifth Amendment as a limitation on the investigatory power of Congress. The first two attempts were less than successful. This comment will discuss the historical background of immunity legislation, and some possible constitutional pitfalls and problems of construction created by the statutory language

Alsop: We Accuse!

A Review of We Accuse! By Joseph and Stewart Also

Admiralty - Warranty of Seaworthiness - Extension to Injury Caused by Appliance Not in Control of Shipowner

Libellant, a longshore foreman for a stevedoring company loading petitioner\u27s ship, was injured when a snatch block broke, causing some loading gear to fall upon his leg. Conflicting evidence in the lower court was resolved by the trial judge, who found that the snatch block was supplied by the stevedoring company. On the basis of this finding, the trial court held that neither the ship nor its appliances were unseaworthy, and that libellant could not recover against the shipowner. The court of appeals reversed and remanded the cause for determination of damages. On certiorari to the Supreme Court, held, affirmed per curiam without opinion. Alaska Steamship Company v. Petterson, 347 U.S. 396, 74 S.Ct. 601 (1954). The Court considered the case governed by Seas Shipping Co. v. Sieracki and Pope and Talbot v. Hawn. Three justices dissented

In-House Digital Workflow for the Management of Acute Mandible Fractures

Computer-aided design and additive manufacturing are revolutionizing oral and maxillofacial surgery. Current methods use virtual surgical planning sessions and custom plate milling via third-party vendors, which is costly and time-consuming, negating the effectiveness in acute facial trauma. This technical note describes a state-of-the-art in-house expedited digital workflow for computer-aided virtual fracture reduction, 3-dimensional printing, and preoperative reconstruction plate adaptation for the management of an acute mandible fracture. This process uses the computed tomographic scan a patient receives in the emergency department or clinic. The DICOM (Digital Imaging and Communications in Medicine) data are transferred into US Food and Drug Administration–approved software, in which the fracture is segmented and virtually reduced based on condylar position, midline symmetries, and occlusion if present. The reduced mandible is then printed, which serves as a template for preoperative reconstruction plate adaptation. This method facilitates a virtually reduced fractured mandible, 3-dimensionally printed model, and ideally adapted plates ready for sterilization before surgery within 2 hours after DICOM upload

The Ursinus Weekly, November 2, 1964

Judy Collins to appear in concert at Ursinus: Agency\u27s first offering to be sell-out • Cafe Montmarte promises to be the unusual • Seven students arrested in mass Halloween uprising: Non-participants fined, spend night in jail • Yale professor speaks to pre-med, chem societies • Helfferich stresses liberal arts importance in Founders\u27 convocation: Four alumni awarded doctorates • Dr. John Clawson, Dean emeritus, dies at home • 19 men receive fraternity bids today in library • Wentz announced business manager • Editorial: Thursday night review • Parleying, partying and panicking portrayed in sorority pledging • Dr. Dooley\u27s assistant gives lecture at Forum • What really happened in the girls\u27 day study? • Sons for Moral America expose nation\u27s decay • The Lantern\u27s deadline posted • Letters to the editor • Hobart squeaks by UC 8-7, in tight game • Cross country gets started • Soccer team loses two by same 2-0 score: Swarthmore 2-0 in 1st half; Haverford downs Bears • Hockey remains undefeated, Beaver and Swarthmore fall • Demas champs; Beta Sig second: Volleyball to start • UC volunteers aid community • Women elect WSGA senate officers • Halloween dance termed something new by Y sponsors • Advice column • Greek gleaningshttps://digitalcommons.ursinus.edu/weekly/1232/thumbnail.jp

Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial

Importance: Psychotic depression is a severely disabling and potentially lethal disorder. Little is known about the efficacy and tolerability of continuing antipsychotic medication for patients with psychotic depression in remission. Objective: To determine the clinical effects of continuing antipsychotic medication once an episode of psychotic depression has responded to combination treatment with an antidepressant and antipsychotic agent. Design, Setting, and Participants: Thirty-six week randomized clinical trial conducted at 4 academic medical centers. Patients aged 18 years or older had an episode of psychotic depression acutely treated with sertraline plus olanzapine for up to 12 weeks and met criteria for remission of psychosis and remission or near-remission of depressive symptoms for 8 weeks before entering the clinical trial. The study was conducted from November 2011 to June 2017, and the final date of follow-up was June 13, 2017. Interventions: Participants were randomized either to continue olanzapine (n = 64) or switch from olanzapine to placebo (n = 62). All participants continued sertraline. Main Outcomes and Measures: The primary outcome was risk of relapse. Main secondary outcomes were change in weight, waist circumference, lipids, serum glucose, and hemoglobin A1c (HbA1c). Results: Among 126 participants who were randomized (mean [SD] age, 55.3 years [14.9 years]; 78 women [61.9%]), 114 (90.5%) completed the trial. At the time of randomization, the median dosage of sertraline was 150 mg/d (interquartile range [IQR], 150-200 mg/d) and the median dosage of olanzapine was 15 mg/d (IQR, 10-20 mg/d). Thirteen participants (20.3%) randomized to olanzapine and 34 (54.8%) to placebo experienced a relapse (hazard ratio, 0.25; 95% CI, 0.13 to 0.48; P \u3c .001). The effect of olanzapine on the daily rate of anthropometric and metabolic measures significantly differed from placebo for weight (0.13 lb; 95% CI, 0.11 to 0.15), waist circumference (0.009 inches; 95% CI, 0.004 to 0.014), and total cholesterol (0.29 mg/dL; 95% CI, 0.13 to 0.45) but was not significantly different for low-density lipoprotein cholesterol (0.04 mg/dL; 95% CI, -0.01 to 0.10), high-density lipoprotein cholesterol (-0.01 mg/dL; 95% CI, -0.03 to 0.01), triglyceride (-0.153 mg/dL; 95% CI, -0.306 to 0.004), glucose (-0.02 mg/dL; 95% CI, -0.12 to 0.08), or HbA1c levels (-0.0002 mg/dL; 95% CI, -0.0021 to 0.0016). Conclusions and Relevance: Among patients with psychotic depression in remission, continuing sertraline plus olanzapine compared with sertraline plus placebo reduced the risk of relapse over 36 weeks. This benefit needs to be balanced against potential adverse effects of olanzapine, including weight gain. Trial Registration: ClinicalTrials.gov Identifier: NCT01427608

Resting state functional connectivity in patients with remitted psychotic depression: A multi-centre STOP-PD study

BACKGROUND: There is paucity of neurobiological knowledge about major depressive disorder with psychotic features ( psychotic depression ). This study addresses this knowledge gap by using resting state functional magnetic resonance imaging (R-fMRI) to compare functional connectivity in patients with psychotic depression and healthy controls. METHODS: We scanned patients who participated in a randomized controlled trial as well as healthy controls. All patients achieved remission from depressive and psychotic symptoms with sertraline and olanzapine. We employed Independent Component Analysis in independent samples to isolate the default mode network (DMN) and compared patients and controls. FINDINGS: The Toronto sample included 28 patients (mean [SD], age 56.2 [13.7]) and 39 controls (age 55.1 [13.5]). The Replication sample included 29 patients (age 56.1 [17.7]) and 36 controls (age 48.3 [17.9]). Patients in the Toronto sample demonstrated decreased between-network functional connectivity between the DMN and bilateral insular, somatosensory/motor, and auditory cortices with peak activity in the right planum polare (t=4.831; p=0.001, Family Wise Error (FWE) corrected). A similar pattern of between-network functional connectivity was present in our Replication sample with peak activity in the right precentral gyrus (t=4.144; p=0.003, FWE corrected). INTERPRETATION: Remission from psychotic depression is consistently associated with an absence of increased DMN-related functional connectivity and presence of decreased between-network functional connectivity. Future research will evaluate this abnormal DMN-related functional connectivity as a potential biomarker for treatment trajectories. FUNDING: National Institute of Mental Health

Plasmas and Controlled Nuclear Fusion

Contains research objectives and reports on four research projects.U. S. Atomic Energy Commission (Contract AT(30-1)-3980)U. S. Atomic Energy Commission (GK-2581